Bausch + Lomb Corporation (NYSE:BLCO) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Bausch + Lomb Corporation (NYSE:BLCO) have been assigned a consensus recommendation of “Hold” from the fourteen analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $17.9167.

Several brokerages recently commented on BLCO. Deutsche Bank Aktiengesellschaft set a $16.00 target price on shares of Bausch + Lomb in a report on Thursday, April 30th. HC Wainwright lifted their target price on shares of Bausch + Lomb from $17.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bausch + Lomb in a report on Monday, April 20th. Wall Street Zen raised shares of Bausch + Lomb from a “hold” rating to a “buy” rating in a report on Saturday, April 18th. Finally, Citigroup set a $19.00 target price on shares of Bausch + Lomb and gave the stock a “buy” rating in a report on Tuesday, June 2nd.

Bausch + Lomb Stock Up 0.1%

Bausch + Lomb stock opened at $14.89 on Friday. The firm has a market capitalization of $5.32 billion, a PE ratio of -24.01, a P/E/G ratio of 0.46 and a beta of 0.58. The company’s 50-day moving average is $15.83 and its 200-day moving average is $16.56. Bausch + Lomb has a fifty-two week low of $11.58 and a fifty-two week high of $18.92. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.53 and a quick ratio of 0.99.

Bausch + Lomb (NYSE:BLCO) last announced its earnings results on Wednesday, April 29th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.22 billion. Bausch + Lomb had a negative net margin of 4.21% and a positive return on equity of 3.60%. Bausch + Lomb’s revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.07) EPS. Sell-side analysts anticipate that Bausch + Lomb will post 0.82 earnings per share for the current year.

Institutional Trading of Bausch + Lomb

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Tudor Investment Corp ET AL bought a new stake in Bausch + Lomb in the 3rd quarter valued at about $2,249,000. Goldentree Asset Management LP boosted its holdings in Bausch + Lomb by 3.0% in the 3rd quarter. Goldentree Asset Management LP now owns 2,660,508 shares of the company’s stock valued at $40,002,000 after purchasing an additional 77,323 shares during the period. Compass Rose Asset Management LP boosted its holdings in Bausch + Lomb by 22.0% in the 3rd quarter. Compass Rose Asset Management LP now owns 1,000,000 shares of the company’s stock valued at $15,070,000 after purchasing an additional 180,000 shares during the period. Oaktree Capital Management LP boosted its holdings in Bausch + Lomb by 28.7% in the 3rd quarter. Oaktree Capital Management LP now owns 3,245,439 shares of the company’s stock valued at $48,909,000 after purchasing an additional 724,194 shares during the period. Finally, Knights of Columbus Asset Advisors LLC bought a new stake in Bausch + Lomb in the 4th quarter valued at about $605,000. Institutional investors own 11.07% of the company’s stock.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.